Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era

Relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients refractory to first line salvage have poor outcomes. Herein we report the outcome of R/R cHL patients requiring ≥two vs. one line in the era of chemo-immunotherapy. Among 55 R/R cHL patients, 33 (60%) required one, 22 (40%) required ≥...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuelgasim, Khadega A, Ghazi, Samer, Alahmari, Bader, Alhejazi, Ayman, Alaskar, Ahmed, Alzahrani, Mohsen, Damlaj, Moussab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581367/
https://www.ncbi.nlm.nih.gov/pubmed/34804792
http://dx.doi.org/10.1016/j.lrr.2021.100276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581367/
https://www.ncbi.nlm.nih.gov/pubmed/34804792
http://dx.doi.org/10.1016/j.lrr.2021.100276

Ejemplares similares